WuXi Apptec (药明康德) IPO: This A+H Listing Will Be Different
Following a fast track A-share listing in May, WuXi AppTec is planning to raise USD 1 bn via an A+H listing. Wuxi AppTec is part of the Wuxi...
1.5k Views
WuXi AppTech IPO Preview: Pharmed Out
WuXi AppTec Co Ltd (603259 CH) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....
1.1k Views
Frontage Holding (方达控股) IPO: More Disclosure Needed to Understand Moat and Growth Prospect
Frontage Holding, a contract research organization subsidiary of A-share listed Hangzhou Tigermed Consulting (300347 CH), filed to list on the Hong...
1.1k Views
WuXi Biologics IPO Review - An Opportunity to Get Exposure to Biologics in China
WuXi Biologics (2269 HK) is looking to raise US$461-511m through the issuance of primary (88%) and secondary (12%) shares. Proceeds will be used...
766 Views
Quick Note - Almost at the Finishing Line
Latest Update:Glass Lewis and ISS have advised Wuxi's shareholders to approve the offer from the consortium. We believe Shareholders will vote in...
437 Views